Immunai
5 articles about Immunai
-
Executives from Israel-based companies express concern about future investment and other operational impacts, as the war rages on in Gaza with tragic loss of life amid political and economic uncertainties.
-
Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed/Refractory Neuroblastoma
5/15/2023
Investigators from Baylor College of Medicine in collaboration with Immunai have published results from a clinical study in which Immunai’s technology helped identify BTG1 as a novel molecular target that can be used to enhance the potency of natural killer T - and T cell-based cancer immunotherapy.
-
Galen Robotics will further benefit from Robert Langer’s extensive experience in biotech startups and hands-on laboratory work.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
The growth includes the tripling of its headcount to 120 employees and more than 30 partnerships with leading universities and institutions.